Myfortic

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

Myfortic for the Treatment of Non-infectious Intermediate Uveitis

A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients

Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring

Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients

Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State

Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®

A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients

Myfortic - Treatment for Extensive cGvHD

Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)

Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients

Enteric Coated Myfortic for Liver Transplant Recipients

Desensitization of Renal Transplant Candidates

Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation

Freedom Study: Myfortic in Kidney Transplant Patients

Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study